ArticleInfectious agents and cancer2011
HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer.
Article in Infectious agents and cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Lineages and sublineages of high-risk human papillomavirus types associated with cervical cancer and precancer: a systematic review and meta-analysis.Journal of the National Cancer Institute · 2025Pooled it
- Human papillomavirus 16 non-European variants are preferentially associated with high-grade cervical lesions.PloS one · 2014Trial
- Characterization of patient-derived HPV16 E6 and E7 variant alleles.Journal of virology · 2026Article
- HPV genotypes in Africa: comprehensive analysis of genetic diversity and evolutionary dynamics.Archives of virology · 2025Article
- Article
- Identification and Functional Implications of the E5 Oncogene Polymorphisms of Human Papillomavirus Type 16.Tropical medicine and infectious disease · 2024Article
- Article
- Epidemiology and survival of cervical cancer in Iran based on national cancer registry data (2008-2014).Frontiers in oncology · 2023Article
- HPV16 E6 gene polymorphisms and the functions of the mutation site in cervical cancer among Uygur ethnic and Han nationality women in Xinjiang, China.Cancer cell international · 2022Article
- Role of HPV 16 variants among cervical carcinoma samples from Northeastern Brazil.BMC women's health · 2020Article
- Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation.Frontiers in public health · 2020Review
- Genetic variations in human papillomavirus and cervical cancer outcomes.International journal of cancer · 2019Article
- Regulation of HPV transcription.Clinics (Sao Paulo, Brazil) · 2018Review
- Transmission between Archaic and Modern Human Ancestors during the Evolution of the Oncogenic Human Papillomavirus 16.Molecular biology and evolution · 2017Article
- HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus.Cancer medicine · 2016Article
- Molecular mechanisms of HPV mediated neoplastic progression.Infectious agents and cancer · 2016Review
- Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang, China.Infectious agents and cancer · 2016Article
- Prevalence of human papillomavirus variants and genetic diversity in the L1 gene and long control region of HPV16, HPV31, and HPV58 found in North-East Brazil.BioMed research international · 2015Article
- Article
- Sequence variation in the E2-binding domain of HPV16 and biological function evaluation in Tunisian cervical cancers.BioMed research international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHPV16 variants are associated with different risks for development of CIN3 and invasive cancer, although all are carcinogenic. The relationship of HPV 16 variants to cancer survival has not been studied.
methods155 HPV16-positive cervical cancers were categorized according to European and non-European variant patterns by DNA sequencing of the E6 open reading frame. Clinico-pathologic parameters and clinical outcome were collected by chart review and death registry data.
resultsOf the 155 women (mean age 44.7 years; median follow-up 26.7 months), 85.2% harbored European variants while 14.8% had non-European sequences. HPV16 variants differed by histologic cell type (p = 0.03) and stage (1 vs. 2+; p = 0.03). Overall, 107 women (68.0%) were alive with no evidence of cancer, 42 (27.1%) died from cervical cancer, 2 (1.3%) were alive with cervical cancer, and 4 (2.6%) died of other causes. Death due to cervical cancer was associated with European variant status (p < 0.01). While 31% of women harboring tumors with European variants died from cervical cancer during follow-up, only 1 of 23 (4.4%) non-European cases died of cancer. The better survival for non-European cases was partly mediated by lower stage at diagnosis.
conclusionsOverall, invasive cervical cancers with non-European variants showed a less aggressive behavior than those with European variants. These findings should be replicated in a population with more non-European cases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.